Search Results

Background : The COVID-19 pandemic led to Cancer Care Ontario’s approval of extended dosing (ED) of pembrolizumab in the management of metastatic non-small cell lung cancer (mNSCLC) as a means of reducing the risk of exposure through less visits

The COVID-19 pandemic has amplified the need for healthcare systems to integrate digital tools, including patient portals, telehealth, and electronic health records, to optimize whole-person cancer care. Pandemic protocols have limited and, in

Background : Significant changes were made in healthcare treatment (tx), safety standards, and protocols during the COVID-19 pandemic. mBC pts are particularly vulnerable to such changes, making it critical to understand their perspectives

oncology centers in relation to the ability to continue enrollment during COVID-19. Figure 1. Enrollment on US MM-6, 2017–2021. Enrollment was uninterrupted, nationwide, during the COVID-19 pandemic. US MM-6 provided an oral, accessible, continuous

radiographic response at her first disease evaluation 2 months into treatment ( Figure 2 ). Figure 2. CT images at (A) treatment initiation, (B) CA 19-9 nadir, (C) treatment hold for COVID-19, and (D) disease progression. The patient’s course

Defining the Problem The COVID-19 pandemic was undoubtedly an accelerator for departures in healthcare. Recruitment and retention have posed challenges in the field for years, but since the pandemic, strategies pertaining to these metrics have

US healthcare systems have been deeply impacted by significant societal shifts over the past several years. The COVID-19 pandemic has changed the way we interact with healthcare, political narratives have impacted how healthcare is perceived and